← Back to Search

Behavioural Intervention

Preconditioning with Tefillin for Heart Disease

N/A
Recruiting
Research Sponsored by Jack Rubinstein
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 days
Awards & highlights
No Placebo-Only Group

Summary

This trial is looking at a new method to help prevent heart attacks. It involves using a technique called "preconditioning" to protect the heart from damage during a heart attack. The researchers observed that

Who is the study for?
This clinical trial is for women over the age of 18 who are not currently taking medication for any medical condition and do not have an active medical condition. It's designed to explore a potential heart protection method observed in Jewish men wearing tefillin.
What is being tested?
The study investigates whether using tefillin, which may induce 'preconditioning', can protect against heart damage during a heart attack. This concept comes from animal studies suggesting preconditioning reduces reperfusion injury when blood flow returns after being blocked.
What are the potential side effects?
Potential side effects are primarily related to Tefillin dermatitis, which includes skin irritation or rash where the tefillin straps come into contact with the skin.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Heart rate variability (HRV)
Secondary study objectives
Inflammatory changes

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: TefillinExperimental Treatment1 Intervention
Wearing of tefillin in traditional manner
Group II: CapsaicinActive Control1 Intervention
Applying cream to non-dominant arm

Find a Location

Who is running the clinical trial?

Jack RubinsteinLead Sponsor
1 Previous Clinical Trials
2 Total Patients Enrolled
~7 spots leftby Apr 2025